Comment by
subaru1 on Jul 12, 2024 10:44am
and MPL can not surpass $0,075 it seems that MPL doesn't participate in that growth. P.S.: Look at AVCN this one is moving and aren't we suppose to be like a partner for the SEDD
Comment by
QContinuum1 on Jul 12, 2024 11:53am
The success of LABS will not be based on the rec market in the US. Market studies on the rec market are pointless as they have nothing to do with the business. There is no way that LABS will penetrate the US market with any of their offerings alone and given LABS doesn't appear to have a partner in the US, nothing will happen in rec there.
Comment by
piduks on Jul 12, 2024 12:34pm
CEO carries too much oxycotin baggage. So many of our citizen killed by it in the U.S. A negative stigma.
Comment by
Olaf123 on Jul 12, 2024 3:41pm
He beleived in the company and wanted to make money but I always wondered if the choice of medipharm was some kind of a tentative for concsience/moral correction.